Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516407 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Electronic (PDF)Add to Basket
EnterprisewideAdd to Basket
Site LicenseAdd to Basket
Live Chat Live Help Software for Website

ASTRAZENECA - Seroquel XR: Para IV Settled with Handa, More to come

MP Advisors, Sep 2011


  Description  
   Products Mentioned   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

AstraZeneca today announced that it has settled paragraph IV litigation for Seroquel XR with Handa pharmaceuticals, who has the first to filer status with 180 days exclusivity. As per the settlement Handa will launch Seroquel XR generics only after November 2016. While litigation is ongoing with other Para-IV filers and a court decision is due. Accord Healthcare – a subsidiary of India based Intas pharmaceuticals has also received tentative approval and poses the most significant threat as the 30-month stay has expired and a court decision should be around the corner. There is a possibility that AZN might settle with Accord as well.



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds